Conception d'une étude clinique visant à traiter la fibrose pulmonaire idiopathique canine par un dérivé polyphénolique

Abstract

CIPF is a chronic disease that mainly affects old dogs of the West Highland White Terrier (WHWT) breed. It causes progressive respiratory failure due to collagen deposition in the pulmonary interstitium. To date, the origin of this disease remains unknown, its diagnosis complex and its pathophysiology little explored. Its prognosis is poor, all the more so as the only treatments currently available are only symptomatic and aimed at improving the dog's quality of life. It is therefore crucial to develop new therapies. Polyphenols, thanks to their anti-fibrosing properties, represent a potentially promising option for the treatment of CIPF. These plant-derived compounds are characterized by a wide range of beneficial effects, including antioxidant, antihypertensive, immunomodulatory, antimicrobial, antiviral and anticancer actions, reinforcing their interest in medicine. The aim of this work is to explore the potential of I2631, a polyphenolic compound, as a treatment for CIPF. It is based on a clinical study conducted at the CVU in Liège, aimed at assessing the efficacy of this derivative in WHWT. Firstly, CIPF and the hypotheses concerning its pathogenesis will be described. Secondly, this work will attempt to summarize the mechanisms of action of polyphenols that may be involved in the treatment of CIPF. Finally, a the clinical trial currently underway at CVU will be briefly outlined.